Arcutis Biotherapeutics Inc. recently held its Q1 2025 Earnings Conference Call on May 6, 2025, to discuss the company's financial results and business updates. Key corporate speakers at the event included Frank Watanabe, President and CEO; Patrick Burnett, Chief Medical Officer; Todd Edwards, Chief Commercial Officer; and Latha Vairavan, Chief Financial Officer. Analysts from various financial institutions such as Morgan Stanley, Guggenheim Securities, Mizuho, TD Cowen, Jefferies, Needham & Company, and HC Wainwright also participated in the call. During the conference call, Frank Watanabe expressed gratitude to David Topper, the retiring CFO, for his contributions and welcomed Latha Vairavan as the new CFO. Watanabe stated, "We wish David all the best in this next stage of life." The company discussed its financial position, highlighting cash and marketable securities of $198.7 million as of March 31, 2025, and a cash burn from operations of approximately $30 million for the quarter. Watanabe projected a positive outlook, indicating, "We expect our quarterly cash burn to continue trending downward as our revenues grow and we approach cash flow breakeven sometime in 2026." The call also addressed the impact of tariffs, which is expected to be minimal compared to other pharmaceutical companies with extensive non-U.S. operations. The full transcript can be accessed through the link below.